Source comparison
Top Melanotan-2 Studies: Research Comparison
Wessells et al. (JAMA) 1996 20 men with psychogenic ED 80% reported spontaneous erections lasting 6–12 hours 0.025mg/kg intranasal, single dose Small sample; no long-term safety data Dorr et al. (Br J Dermatol) 2006 40 fair-skinned adults 3.5-fold increase in
This comparison does not assign a generated winner or score.
- Wessells et al. (JAMA)
- 1996
- 20 men with psychogenic ED
- 80% reported spontaneous erections lasting 6–12 hours
- 0.025mg/kg intranasal, single dose
- Small sample; no long-term safety data
- Dorr et al. (Br J Dermatol)
- 2006
- 40 fair-skinned adults
- 3.5-fold increase in minimal erythema dose (MED) after 60 days
- 0.16mg/kg subcutaneous over 60 days
- No cancer incidence outcomes measured
- Greenway et al. (Obesity)
- 2002
- 12 obese adults (BMI 32–38)
- 9% mean body weight reduction over 12 weeks
- 0.5–2.0mg daily subcutaneous escalating
- High nausea rate (60%); weight regain post-cessation
- Martin et al. (J Sex Med)
- 2003
- 40 men with mixed-origin ED
- 65% response rate at therapeutic doses
- 0.025mg/kg intranasal repeated dosing
- Transient blood pressure elevation in 30% of subjects
- Van der Ploeg et al. (Peptides)
- 2008
- 18 volunteers (skin biopsy cohort)
- Increased melanocyte dendrite formation without proliferation
- 0.16mg/kg subcutaneous for 28 days
- Histological endpoints only; no functional outcomes
- Bottom Line / Professional Assessment
- .
- Strongest evidence supports erectile function improvement in psychogenic ED; photoprotection effects are documented but cancer prevention unproven; appetite suppression is real but side-effect limited and non-durable
- Therapeutic doses cluster at 0.025–0.16mg/kg; recreational doses often exceed this 3–10x
- No Phase 3 trials completed for any indication; off-label use far exceeds evidence base